![Help 4 HD Live! artwork](https://is5-ssl.mzstatic.com/image/thumb/Podcasts123/v4/d7/6f/33/d76f33bd-de2e-5600-63bf-52295b1c801e/mza_3103069902989466564.jpg/100x100bb.jpg)
Help 4 HD News Update with First HD
Help 4 HD Live!
English - October 08, 2013 22:30 - 51 minutes - 11.5 MB - ★★★★★ - 11 ratingsHealth & Fitness clinical trial education hd research neuropsychiatry neurology hd & jhd education Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
PRE-RECORDED - First-HD is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months.
Tonight listen to our special guests Dr. Samuel Frank - Associate Professor of Neurology and co-Director of Neurology Resident Education at Boston University and is involved with many HSG studies and trials, and David Stamler - Chief Medical Officer at Auspex Pharmaceuticals.
Help 4 HD International Inc. is thrilled to be working with Auspex and HSG as their premiere communications partner.